Scilex Pharmaceuticals, Inc. (United States)

Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The company's lead product ZTlido® is a marketed prescription lidocaine topical product approved by the U.S. FDA for relief of pain associated with Post-Herpetic Neuralgia. Scilex has also acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®.

Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products. The company's lead product ZTlido® is a marketed prescription lidocaine topical product approved by the U.S. FDA for relief of pain associated with Post-Herpetic Neuralgia. Scilex has acquired two FDA approved non-opioid pain products, GLOPERBA® and ELYXYB®. ELYXYB® was launched in the U.S. in April 2023, and GLOPERBA® was launched on June 10th, 2024.

• ZTlido®

  A marketed prescription lidocaine topical product approved by the U.S. FDA for relief of pain associated with Post-Herpetic Neuralgia.

• GLOPERBA®

  Indicated for the prophylaxis of gout flares in adults.

• ELYXYB®

  Indicated for the acute treatment of migraine with or without aura in adults.

1. 1Scilex Holding – Striving to Revolutionize the World of Pain Managementscilexholding.com
2. 2About – Scilex Holdingscilexholding.com
3. 3Scilex Pharmaceuticals, Inc. (United States)wikidata.org